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 2 
Eukaryotic microbial pathogens are major contributors to illness and death 34 
globally but much of their impact can be controlled by drug therapy. However, 35 
as with prokaryotic microbes, the emergence of drug resistance has threatened 36 
these treatment efforts. Here, we discuss the challenges posed by eukaryotic 37 
microbial pathogens and how these are similar to, or differ from, the challenges 38 
of prokaryotic antibiotic resistance. The therapies used for several major 39 
eukaryotic microbes are then detailed and the mechanisms that they have 40 
evolved to overcome these described. The rapid emergence of resistance and 41 
the restricted pipeline of new drug therapies pose significant risks to global 42 
health and are particularly acute in the developing world.  Nonetheless, we detail 43 
how an integration of new technology, biological understanding, epidemiology 44 
and evolutionary analysis can help sustain existing therapies, anticipate the 45 
emergence of resistance or optimise the deployment of new therapies. 46 
 47 
The identification and use of antibiotics presents one of the great medical 48 
achievements of the 20th Century, saving countless lives by controlling the risk of 49 
infection from contagion, after injury, surgery or in immunosuppressed individuals. 50 
However, in only 80 years since the introduction of penicillin, resistance to a broad 51 
range of antibiotic drugs has become widespread, with the compounded risk from 52 
multi-drug resistant bacterial infections severely limiting treatment options. This has 53 
created justified concern and global attention, not only in the medical community but 54 
also at Government level, in the media and the public1. 55 
Whilst predominantly applied to control prokaryotic microbial infections, the 56 
threat of disease from eukaryotic microbes has also been contained by therapeutic 57 
drugs - preventing or controlling disease caused by eukaryotic parasites and fungi in 58 
both a human and animal health setting. These represent some of the most important 59 
disease-causing agents (Table 1), particularly in the tropics where the distribution of 60 
the pathogen is frequently linked to the distribution of the arthropods that act as 61 
disease vectors. Such vector-borne parasites include malaria (Plasmodium spp.) and 62 
kinetoplastid parasites (Trypanosoma cruzi, causing Chagas’ disease; Trypanosoma 63 
brucei gambiense and T. b. rhodesiense causing human African trypanosomiasis 64 
(HAT), and 17 Leishmania spp. causing a variety of cutaneous and visceral diseases). 65 
Other clinically important protozoan parasite species not considered in this review are 66 
transmitted either orally (Toxoplasma, Giardia and Entamoeba) or venereally 67 
(Trichomonas).  Distinct from the many obligate eukaryotic unicellular parasites, 68 
opportunistic fungal pathogens are global in distribution and include Candida, 69 
Aspergillus spp., Cryptococcus and Pneumocystis spp.  70 
 3 
The control of these eukaryotic pathogens has often involved therapies 71 
predating the use of penicillin and in some cases with unacceptable toxicity profiles2.  72 
Nonetheless, as with the rise of antimicrobial resistance in bacteria, resistance has or 73 
is emerging in the therapies targeting these eukaryotic microbes, with potentially 74 
devastating consequences for exposed populations. This, however, has received far 75 
less attention despite some commonality in its underlying causes. In this perspective, 76 
we detail how the control of eukaryotic microbes poses both similar and distinct 77 
challenges to that of bacterial pathogens, the drugs used to combat these pathogens 78 
and the resistance mechanisms they are evolving. Finally we discuss how the latest 79 
methodological approaches can anticipate the emergence of drug resistance and 80 
support the development of new therapeutic approaches, either through the 81 
development of new drugs, the maintenance of existing therapies or through the use 82 
of alternative approaches to limit the spread of drug resistance. 83 
 84 
Common challenges for the control of prokaryotic and eukaryotic microbial 85 
pathogens. 86 
 87 
The challenges in the control of eukaryotic microbial pathogens share many similarities 88 
with bacterial infections. Both replicate more rapidly than their hosts, such that 89 
resistance can be selected within a relatively short timescale within a treated host 90 
population. This is exacerbated by inappropriate treatment profiles, leading to 91 
subcurative exposure in the context of infection3. Problems of sub optimal dosing are 92 
particularly acute when applied to tropical parasites. For example, for antimalarials, up 93 
to 35% of drugs may be of poor quality, have poor packaging and labelling or be 94 
falsified4. With lower than optimal concentrations of the active agent, this rapidly 95 
selects resistance in exposed populations, as does underdosing resulting from self-96 
prescription. Where zoonoses are concerned, such as with African trypanosomes, 97 
parasite selection in livestock populations treated with trypanocides in a context where 98 
there is poor supply chain management, fraudulent provision or cost barriers to optimal 99 
dosing, can also lead to resistance emergence. This represents a significant threat 100 
where up to 50 million doses of trypanocides are used in sub-Saharan livestock 101 
annually, mainly as a preventative, and trypanocides represent 45% of animal health 102 
costs. Agricultural use of fungicides might also contribute to the selection of azole 103 
resistant Aspergillus fumigatus5, mirroring the situation with antibiotic exposure in 104 
veterinary contexts for bacterial infections, where environmental contamination 105 
generates significant regulatory concern6.  106 
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A further similarity between bacterial and eukaryotic microbial pathogens is the 107 
phenomenon of persister populations7.  This is the survival of a fraction of the 108 
population of pathogens following exposure to a chemotherapeutic agent (or vaccine). 109 
These can then re-establish patent infection whilst remaining drug sensitive (see 110 
review8).  The state of persistence is not heritable and resistance is not due to genetic 111 
alterations directly linked to rendering a drug ineffective.  Rather, persistence is a 112 
physiologically active state involving pathogen response to the assault which is 113 
initiated upon demand.  Persistence ensures incidental survival but does not future-114 
proof a pathogen as genetically heritable resistance would. However, the combination 115 
of persisters and sub-optimal drug dosage might form an enhanced reservoir for the 116 
emergence of resistance and may even provide a population pre-disposed to evolve 117 
resistance more readily.  An example of this relating to parasite dormancy is the 118 
resistance of Plasmodium falciparum to artemisinin (and other antimalarials such as 119 
mefloquine, atovaquone), which was first characterised by degrees of persistence 120 
followed by the emergence of genomic changes now causally associated with 121 
resistance (see below). Similarly, fungal infections (e.g. C. albicans) associated with 122 
biofilms are a good example of persister populations analogous to those in bacterial 123 
communities9-11. The duration of persistence can range from days (P. falciparum) to 124 
lifelong (e.g. C. albicans).  Mechanisms of persistence vary – they may emerge 125 
spontaneously possibly through stochastic changes in gene expression that prepare a 126 
population of pathogens for survival in varying environmental conditions (“bet 127 
hedging”). This is best described in bacteria12 but is a phenomenon recently 128 
characterised in P. falciparum13.  Furthermore, environmental signals may induce 129 
persistence such as the nutrient starvation typically encountered by C. albicans in 130 
biofilms9,14.  131 
 132 
Distinct challenges for the control of prokaryotic and eukaryotic microbial 133 
pathogens. 134 
 135 
Although bacterial and eukaryotic microbes share common features with respect to 136 
their responses to drug exposure, there are also differences that particularly challenge 137 
the control of eukaryotic pathogens. First, eukaryotic microbes are more similar to their 138 
hosts than prokaryotic pathogens in terms of their biochemistry and metabolism, 139 
genetic composition, cell architecture and biology. Consequently, drugs targeting 140 
eukaryotic microbes must focus on differences from the eukaryotic norm, or particular 141 
specialisms of each pathogen group. This restricts the cross-specificity of drugs, such 142 
that there are distinctions in sensitivity between different apicomplexans (malaria, 143 
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toxoplasma) or between the evolutionarily divergent trypanosomes, T. brucei spp. and 144 
T. cruzi.  Comprising a different evolutionary kingdom, fungi have many differences 145 
from other eukaryotic microbial pathogens, again necessitating drugs to be developed 146 
for, and targeted to, a particular pathogen. This increases the challenges for drug 147 
development and inevitably constricts the new drug pipeline. 148 
Second, many eukaryotic microbial pathogens have evolved a parasitic life 149 
style distinct from the opportunistic infections characteristic of most bacterial 150 
pathogens (but also fungi). The evolution of parasitism is often accompanied by the 151 
development of sophisticated immune evasion mechanisms, which promotes the 152 
impact of persister phenotypes described earlier. Specifically, bacteriostatic drugs can 153 
operate to clear infection in concert with the immune system15.  However, drugs that 154 
generate cytostatic rather than cytocidal responses in infection with an 155 
immunosuppressive parasite can lead to recrudescence upon the removal of drug 156 
exposure. This, in turn, can predispose the population to the selection for drug 157 
resistance. Similarly the adaptation to an intracellular life style or particular body niche 158 
can protect parasites from drug exposure, a feature shared with some bacterial 159 
pathogens that have evolved to survive in cells rather than systemically (Legionella, 160 
Mycobacteria). 161 
A third challenge relates to the clinical diagnosis and the screening for drug 162 
resistance in eukaryotic microbial pathogens16.  In bacterial infections, screening for 163 
the sensitivity to antibiotics is straightforward and routine. In contrast, eukaryotic 164 
parasites can require highly-specialised growth media and considerable growth 165 
periods to determine their susceptibility or otherwise to potential drug therapies. Also, 166 
unlike bacterial susceptibility testing where a Minimum Inhibitory Concentration (MIC) 167 
is determined, most parasitologists report EC50-values without providing the Hill slope 168 
of the growth inhibition curve or calculating the EC90 value.  It is perfectly possible to 169 
obtain a resistant line with an identical EC50 to the susceptible isolate, yet that is still 170 
resistant due to a shallower Hill slope.  As a consequence clinical diagnosis and the 171 
selection of the appropriate clinical management can be slow, or practically impossible 172 
in the context of all but the most specialised laboratories. 173 
A fourth distinction from common bacterial infections is the economic challenge 174 
of treating diseases of the developing world. Diseases such as malaria, 175 
trypanosomiasis, leishmaniasis and cryptococcosis are common in the poorest parts 176 
of the world where the economic capacity to develop or deliver treatments are very 177 
limited and restricted to philanthropic and charitable donations, or the concerted 178 
actions of multi-Government agencies. This makes the threat of drug resistance even 179 
more acute, because there is not the financial incentive to develop new drugs to 180 
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replace those to which resistance emerges. Nonetheless, certain major 181 
pharmaceutical companies are increasingly engaged in Public Private Partnerships 182 
providing access to chemical compound collections and other resources to discover 183 
and develop new drugs for neglected tropical diseases.  Excellent examples of this 184 
collaborative spirit include the Medicines for Malaria Venture (http://www.mmv.org/), 185 
the Drugs for Neglected Diseases initiative (http://www.dndi.org/) and the Tres Cantos 186 
Open Lab Foundation (http://www.openlabfoundation.org/). 187 
 One route to limit the impact of drug resistance has been the exploitation of 188 
combination therapies for parasitic infections. This approach has proved useful for 189 
cancer therapy as well as for the treatment of TB, leprosy and viral infections such as 190 
HIV. It has also been encouraged for parasitic infections, for example through 191 
artemisinin combination therapy17,18 to limit the emergence and spread of artemisinin-192 
resistant malaria, and for trypanosomes where nifurtimox/eflornithine combination 193 
therapy19 is proving more robust than eflornithine-based therapy alone. However, 194 
combination therapies for parasitic diseases require the availability of more than one 195 
effective drug or drug class, which is not always the case. Moreover, combination 196 
therapies have been often embraced only when resistance is already detected to one 197 
of the front line monotherapies, allowing multidrug resistant parasites to be selected. 198 
Here, the use of drug combinations with different pharmacokinetics in plasma, as with 199 
artemisinin and piperaquine, can limit resistance emergence20.  However, the cost of 200 
drugs for many parasites of the developing world can generate geographical 201 
discrepancy in the use of mono and combination therapies. Here, the efficacy of 202 
combination therapies can be threatened by ingression of resistant parasites selected 203 
under monotherapy. 204 
The final challenge for eukaryotic microbes that differs from many prokaryotic 205 
and viral pathogens has been the failure to formulate and use effective vaccines to 206 
prevent infection21.  Malaria research has focused intensively on vaccine development 207 
without transformative success, whereas for African trypanosomes the immune 208 
evasion mechanism employed by the parasite (antigenic variation) effectively renders 209 
vaccine approaches impossible. Other kinetoplastids have also proved challenging to 210 
produce safe effective vaccines, despite the widespread early use of ‘leishmanization’ 211 
for the cutaneous form of leishmaniasis, which has the risk of virulence in some 212 
individuals and immunosuppression22.  Fungal pathogens have their greatest impact 213 
in immunocompromised individuals rendering vaccines potentially less useful. At 214 
present there are no licenced fungal vaccines; nonetheless, there are promising 215 
developments for adhesion-like substance 3 (Als3) and secreted aspartic protease 2 216 
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(Sap2) based vaccines, although concerns have been raised over their univalency and 217 
the potential for C. albicans to circumvent their efficacy23. 218 
 219 
Drugs used against different eukaryotic microbes and examples of the 220 
resistance mechanisms against them  221 
 222 
Throughout evolution microorganisms have evolved numerous strategies to counteract 223 
cellular toxicity induced by diverse chemical stresses (xenobiotics, metals, reactive 224 
oxygen and reactive nitrogen species, etc).  Many of these generic defences have 225 
been co-opted for drug resistance. Figure 1 summarises the major therapeutic agents 226 
used to target malaria, kinetoplastid parasites and fungi, highlighting the dates of 227 
introduction and the appearance of resistance for each. The principal methods of 228 
resistance (Figure 2) involve either reduction of the free drug level at the target site of 229 
action, alterations in the drug target reducing its drug binding affinity or over-expression 230 
of the target restoring its essential function.  In the case of inhibition of a metabolic 231 
pathway, the essential end-product can be produced either by induction of an 232 
alternative pathway or by upregulation of a salvage pathway in order to obtain an 233 
essential metabolite from the host.  Downstream consequences of target inhibition 234 
include damage to DNA, proteins and lipids such that upregulation of repair pathways 235 
can also contribute to resistance.  Unlike bacteria, acquisition of resistance genes by 236 
lateral gene transfer on plasmids has not been observed for protozoan parasites or 237 
fungal pathogens. In Table 2 we summarise the drugs used to treat eukaryotic 238 
microbial pathogens, their mode of action and mechanisms of resistance where 239 
known. Below, we highlight specific examples where drug resistance or the threat of 240 
resistance challenges current control efforts. 241 
 242 
Malaria:  243 
The most successful antimalarial in history to date has been chloroquine (CQ), a 4-244 
aminoquinoline derivative of quinine (itself the world’s first mass-distributed 245 
antimalarial) and first synthesized in 193424.  CQ was cheap and remained effective 246 
for decades. However, due to massive overuse and suboptimal compliance, resistance 247 
to chloroquine emerged in Southeast Asia in 1957 and in South America in 1960, and- 248 
by the mid 1980’s- it was barely possible to use even in Africa25. Whilst disputed by 249 
some26 the leading candidate for resistance to CQ (CQR) is PfCRT (P. falciparum CQR 250 
transporter)27. However, despite reports that PfCRT functions as a chloride channel, a 251 
proton pump, an activator of Na+/H+ exchangers or a cation channel, the physiological 252 
function of PfCRT remains unclear28. Nonetheless, PfCRT is central to much 253 
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antimalarial resistance, the precise profile of which is modulated by associated 254 
mutations in other genes. 255 
Artemisinin and its derivatives are fast acting but short-lived antimalarials that 256 
have been globally successful. In particular artemisinin-based combination therapies 257 
(ACTs, e.g. artemether-lumefantrine, artesunate-amodiaquine, and 258 
dihydroartemisinin-piperaquine) were recommended by the WHO in 2001 to ensure 259 
high cure rates of falciparum malaria and to reduce the spread of drug resistance to 260 
other front line drugs. However, clinical resistance was confirmed in 200829 261 
characterised by a failure to rapidly clear parasites in patients around the Thai-262 
Cambodian border30,31. Resistant parasites were characterized by transcriptomics32, 263 
large scale whole genome sequencing (WGS) of clinical isolates33,34 and classical 264 
generation of resistant mutants by in vitro culture followed by WGS35. This pinpointed 265 
multiple independent mutations in a gene encoding a Kelch propeller protein (Kelch 266 
13) which was then causally linked to resistance by reverse genetics36,37.  Large-scale 267 
genomic epidemiological evidence suggests that artemisinin resistance is not as 268 
straightforward as the simple acquisition of mutations in kelch13.  Indeed, 269 
nonsynonymous mutations in ferredoxin, apicoplast ribosomal protein S10, multidrug 270 
resistance protein 2 and the chloroquine resistance transporter (PfCRT) also showed 271 
strong associations with artemisinin resistance29.  These mutations appear to act as 272 
markers of a genetic landscape upon which artemisinin resistance-conferring 273 
kelch13 mutations are more likely to occur.  These landscape mutations also correlate 274 
with the current geographical limits of artemisinin resistance29.  This concept is further 275 
supported by additional genomic epidemiological evidence that demonstrates many of 276 
the 20 or so mutations in kelch13 that have been implicated in the SE Asian 277 
manifestation of artemisinin resistance are also found in African PF isolates.  However, 278 
these mutations are present at no greater frequency in the African strains than other 279 
PF genes indicating a lack of selective pressure in that continent and that these strains 280 
lack the enabling genetic background observed in SE Asia38. 281 
Kelch propeller domain proteins are subcellular organisers of multiprotein 282 
complexes and indeed artemisinin resistance associated mutation of Kelch 13 results 283 
in its enhanced association with phosphatydylinositol-3-Kinase (PI3K)39.  Experimental 284 
overexpression of PI3K results in enhanced artemisinin resistance and PI3P levels are 285 
predictive of resistance to artemisinin39. In addition, upregulation of the chaperonin 286 
complexes, PROSC and TRiC, involved in the unfolded protein stress response in 287 
other eukaryotes, may contribute to artemisinin resistance32.  Worryingly, resistance to 288 
some of the various ACT regimens (involving lumefantrine and amodiaquine and 289 
PfCRT) is becoming evident40-43. However the framework for the rapid evaluation of 290 
genome evolution in the face of drugs is in place and will hopefully swiftly indicate any 291 
further potential mechanisms. 292 
 293 
 294 
Human African trypanosomiasis:  295 
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The vast majority of reported cases of HAT are caused by T. b. gambiense, with less 296 
than 2% caused by T. b. rhodesiense44.  Treatment involves either pentamidine or 297 
suramin for stage 1 infection (before CNS involvement) whereas melarsoprol, 298 
eflornithine or nifurtimox/eflornithine combination therapy are used once the parasite 299 
crosses the blood-brain barrier2, the latter combination therapy reducing the duration 300 
of treatment regimens.  Given the limited chemotherapeutic options for the treatment 301 
of HAT (Table 2), drug resistance could seriously compromise efforts to eliminate this 302 
epidemic disease as a public health problem44. Fortunately, resistance emergence for 303 
pentamidine has not been significant, despite continuous use of pentamidine since the 304 
1940s, including a mass chemoprophylactic campaign in the 1950s in the then Belgian 305 
Congo. However, cross resistance to pentamidine and melarsoprol, used for stage 2 306 
of infection, is frequently observed. Melarsoprol is a trivalent melaminophenyl arsenical 307 
which has a propensity to react covalently with vicinal dithiols, including the parasite-308 
specific dithiol, trypanothione45, to form a cyclic complex known as MelT46. Melarsoprol 309 
has a high incidence of severe (lethal) toxicities and high rates of treatment failures 310 
have been reported in the Democratic Republic of Congo, Uganda, Angola and 311 
Sudan2.  Although therapeutic failure does not necessarily equate with drug resistance, 312 
it appears that the high relapse rate in northwest Uganda is associated with reduced 313 
susceptibility to melarsoprol47,48. The recent report that the aquaglyceroporin AQP2 314 
appears to function as a transporter for large drugs such as pentamidine and 315 
melarsoprol was surprising given that Aquaglyceroporins are channels facilitating the 316 
passive transport of water and small neutral molecules across cell membranes.  317 
Nonetheless, there is strong evidence that AQP2 is indeed synonymous with the high 318 
affinity pentamidine transporter (HAPT1)49, with a recent report indicating that 319 
pentamidine binds and inhibits the transporter and is then internalised via 320 
endocytosis50. 321 
 322 
Chagas’ disease:  323 
For Trypanosoma cruzi, an intracellular parasite with a wide tissue tropism, infection 324 
has three phases: an acute phase associated with high parasitaemia; an asymptomatic 325 
(indeterminate) phase lasting anywhere between 10-30 years, where parasitaemia is 326 
controlled by the immune response; and a chronic phase in about 30-40% of patients 327 
characterised by either cardiac disease or digestive disease (mega-oesophagus and 328 
mega-colon). For treatment, benznidazole and nifurtimox have significant activity in 329 
the acute phase51 and benznidazole also eliminates parasitaemia in the indeterminate 330 
and chronic phases of the disease52,53.  However, a large multi-centre, randomized trial 331 
of benznidazole for chronic Chagas’ cardiomyopathy failed to significantly reduce 332 
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cardiac clinical deterioration through 5 years follow-up53.  Whether this is due to 333 
differences in drug susceptibility, pharmacokinetic/pharmacodynamic issues or the 334 
pathophysiology of the disease is not known.  The results of two recent clinical trials 335 
with azole ergosterol inhibitors, posaconazole and E1224 (a pro-drug of ravuconazole) 336 
have been equally disappointing52,54,55. 337 
 338 
 339 
Visceral leishmaniasis:  340 
Treatment of visceral leishmaniasis (VL), cutaneous and mucocutaneous 341 
leishmaniasis is limited to four main drugs: pentavalent antimonial complexes (sodium 342 
stibogluconate and meglumine antimonate); amphotericin B (as deoxycholate or 343 
liposomal formulations); the aminoglycoside paromomycin; and the 344 
alkylphosphocholine miltefosine56,57.  Treatment varies according to geographical 345 
location, the immune status and other co-morbidities of the patient, and the disease 346 
classification58. 347 
Of these treatments, widespread resistance to antimonial drugs is specific to 348 
Southern Asia and not in Sub-Saharan Africa or Brazil.  Indeed, antimonial drugs are 349 
not recommended in India or Nepal due to treatment failures commencing in the 1990s 350 
and now reported to be as high as 60% in some regions59.  This has been attributed to 351 
inappropriate treatment in an unregulated private health system or to the use 352 
substandard antimonial drugs.  However, Southern Asia is the only region where 353 
arsenic exposure and widespread antimonial resistance co-exist.  Thus, environmental 354 
pollution and exposure of patients to arsenic in food and drinking water was proposed 355 
as an alternative hypothesis60.  Arsenic and antimony are both metalloids and selection 356 
of leishmania parasites for resistance to trivalent arsenic results in cross-resistance to 357 
trivalent antimony in vitro61, but its physiological relevance was uncertain.  Chronic 358 
exposure of infected mice to arsenic in drinking water at environmentally relevant 359 
levels demonstrated that it is possible to generate resistance to pentavalent antimony 360 
in vivo62.  A retrospective clinico-epidemiological study identified a trend towards 361 
increased treatment failure in arsenic exposed patients, but failed to reach statistical 362 
significance63. 363 
   364 
Resistance to antimonials is multifactorial and most of the mechanisms shown in 365 
Figure 2 have been implicated in Leishmania.  Studies on experimental and clinical 366 
resistant isolates strongly support the hypothesis that trypanothione plays a pivotal role 367 
in antimonial resistance.  However, none of the following mechanisms are universal in 368 
resistant isolates.  Decreased biological reduction of SbV to SbIII has been reported in 369 
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resistant leishmania amastigotes64 and two candidate “antimony reductases” 370 
identified, although genetic65,66 and proteomic studies67,68 have not identified any 371 
changes in either TDR169 or ArsC70.  The mechanism of uptake of SbV is not known, 372 
but modulation of expression of aquaglyceroporin 1 (AQP1) affects SbIII susceptibility71-373 
73.  AQP1 copy number and expression levels correlate with susceptibility to SbIII in 374 
some, but not all, clinical isolates74,75.  However, interpretation of this observation is 375 
complicated by the fact that AQP1 is located on chromosome 31, which is frequently 376 
trisomic or tetrasomic76 in these mosaic aneuploid parasites77. Upregulation of 377 
trypanothione and ancillary biosynthetic pathways has also been observed in 378 
genomic65,66 and metabolomic78,79 studies. MRPA is responsible for ATP-dependent 379 
efflux of SbIII as a thiol conjugate into membrane vesicles80 and a homodimeric ABC 380 
half-transporter (ABCI4) is one possible candidate for efflux across the plasma 381 
membrane81.   382 
Miltefosine, the only oral treatment for VL, was first approved for use in India in 383 
2002.  However, a decade on there is an increasing rate of clinical relapse82,83, which 384 
threatens to undermine the Kala-Azar Elimination Program in the Indian subcontinent. 385 
Stable resistance is readily generated in the laboratory with no cross-resistance to 386 
other anti-leishmanial drugs84,85.  387 
 388 
Fungi:  389 
Several classes of antifungals are used clinically (Table 1, Table 2) – each with very 390 
different drug resistance profiles. The oldest antifungals are the polyene macrolide 391 
antibiotics, exemplified by amphotericin B, which remains a front-line choice of a broad 392 
spectrum agent for fungal infections of unknown aetiology. Amphotericin deoxycholate 393 
has significant nephrotoxicity which is significantly ameliorated in lipid carrier 394 
formulations such as AmBisome, which also has potent anti-Leishmania activity. As 395 
with other eukaryotic pathogens, resistance to antifungal drugs has become an 396 
increasing important clinical problem86,87.  A few recognised cases exist of inherent 397 
resistance of specific fungi to specific antifungals, but mostly resistance is due to 398 
induced changes and mutations.  399 
The imidazoles and more modern triazoles (collectively known as the “azoles”) 400 
constitute the main class of antifungals used in the treatment of infections. Various 401 
modifications of the triazole ring have generated a series of antifungals including 402 
fluconazole (used mainly in the treatment of Candida infections), and itraconazole, 403 
voriconazole, posaconazole, ravuconazole and the recently licenced isavuconazole 404 
which have improved activity against Aspergillus and filamentous fungal species.  405 
These compounds have important differences in antifungal potencies, spectrum of 406 
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activities, bioavailability, drug interactions and toxic potential.  For example, some 407 
patients treated with voriconazole suffer from photosensitivity and an elevated risk of 408 
skin carcinoma88.  Other sterol inhibitors include the allylamines squalene epoxidase 409 
inhibitors and phenylmorpholine Erg24 D14 reductase and Erg2 D8-D7 isomerase 410 
inhibitors that are used topically against dermatophytic infections for which clinical 411 
resistance is low.   412 
Although some fungi such as Candida krusei are inherently azole resistant, 413 
multiply triazole resistant strains are now emerging89,90 as well as strains with cross 414 
resistance to azoles and echinocandins suggesting worrisome multi-drug resistance 415 
(MDR) phenotypes in medically important fungi91.  A threat from multi-azole resistant 416 
strains of A. fumigatus may have arisen under the selective pressure of agricultural 417 
azole fungicides and subsequent transmission of azole resistant strains to the clinic by 418 
spore dispersal92-95. The prevalence of these alleles is increasing in Europe and now 419 
in other parts of the world90,96,97.  In Candida mutants harbouring azole resistance have 420 
a fitness deficit98; however, MDR strains of Aspergillus do not seem to have 421 
significantly decreased fitness implying they may become stably represented in the 422 
environment. 423 
The most recently developed major class of antifungal are the echinocandin 424 
antibiotics of which caspofungin, micafungin and anidulafungin are used clinically.  425 
These have similar pharmacokinetic properties although a new echinocandin (CD101- 426 
formerly Biofungin) is in clinical trials and has improved stability in vivo and requires 427 
less frequent i.v. dosing. Echinocandins are fungicidal against Candida species and 428 
fungistatic or fungicidal against Aspergillus causing hyphal or bud tip lysis but they are 429 
not efficacious against Pneumocystis jiroveci and some other species. 430 
Hsp90-mediated changes in drug tolerance have also been implicated in 431 
determining echinocandin sensitivity99.  Recently, multi-drug azole/ echinocandin 432 
resistance has been identified in fungi and this is particularly frequent in strains of 433 
C. glabrata which is common in patients with haematological malignancies and solid 434 
tumours100,101.  These MDR strains of C. glabrata become reliant on i.v. amphotericin 435 
treatment, and since this agent has poor penetration into urine such infections are 436 
essentially untreatable. 437 
 438 
 439 
Outstanding challenges and future prospects 440 
 441 
This review began by highlighting the similarities and differences between drug 442 
resistance emergence in prokaryotic and eukaryotic microbes. The control of the 443 
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emergence of drug resistance for eukaryotic microbial pathogens also has similarities 444 
and distinctions from prokaryotic drug resistance, and our challenge for the future is to 445 
ensure best practice is employed for both groups. One effective mechanism to control 446 
drug resistance spread in bacterial pathogens is the application of appropriate 447 
antibiotic stewardship, applying the right drug at the right dose, at the right time, for the 448 
right duration. This approach operates effectively where there is well-regulated 449 
healthcare, effective and rapid screening, a selection of available drugs as contingency 450 
and the necessary education and engagement between the patient and healthcare 451 
provider. Moreover, bacterial drug resistance is a global phenomenon where 452 
resistance selected through poor stewardship in one geographical area may be 453 
contained by stringent practices in other areas, or combatted by an investment in new 454 
pharmaceutical development in wealthy countries. These containment measures are 455 
inevitably less effective where primary care is limited or too expensive, education is 456 
lacking or where the diseases involved do not have direct impact in the developed 457 
world. In consequence, the limitation of many eukaryotic pathogens to the poorer parts 458 
of the world makes a co-ordinated response to resistance emergence more difficult to 459 
achieve. 460 
 The drivers of resistance emergence are also more difficult to mitigate for many 461 
eukaryotic pathogens. As highlighted earlier, drug provenance and effective delivery 462 
is a significant challenge in the developing world. The latter is a particular challenge 463 
for prospective mass drug administration programmes where delivery to a population 464 
on a broad or local scale, if incomplete, can counteract its intention to contain the 465 
spread of existing resistance in target regions. A further complication in low and 466 
middle-income countries is the effects of co-infection or malnutrition in populations 467 
treated with drugs targeting a particular pathogen (discussed in 102). Notably, the 468 
pharmacokinetic behaviour of drugs in malnourished individuals may be variable and 469 
unpredictable leading to inadvertent under-dosing, driving resistance emergence. 470 
When combined with immunosuppression induced by many parasites, or the hospital-471 
induced immunosuppression of patients that become susceptible to fungal infection, 472 
drug concentrations that would clear infections in the context of a robust immune 473 
system may fall short in its absence. The ecological balance between distinct 474 
pathogens in patients with coinfections can also lead to unanticipated consequences, 475 
where the removal of one pathogen can create a niche exploited by a distinct pathogen 476 
or where the normal interactions between pathogens with each other, and with the 477 
immune system, is perturbed with drug pressure. The resistance mechanisms selected 478 
in drug treated populations can also alter pathogen phenotypes with the risk of 479 
enhanced virulence. 480 
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Although the factors that drive drug resistance are well known, it remains 481 
essential to identify when drug resistance arises and to respond rapidly and effectively. 482 
As with health care, surveillance is a key challenge for diseases in the developing 483 
world, where populations may be inaccessible, reluctant to engage or where treatment 484 
failure can have multiple causes beyond the emergence of drug resistance. Moreover, 485 
resistance can show considerable variation amongst populations or in different 486 
geographical settings. Here, accurate and rapid detection is critical to understand 487 
resistance epidemiology and thereby the best treatment to deliver, but this can be 488 
difficult to achieve. Despite this, developments in field PCR assays and next generation 489 
sequencing permit the sensitive identification and tracking of emergent resistance, 490 
allowing earlier control responses than could be previously achieved. Hence, an 491 
integration of improved therapeutic delivery and treatment monitoring are critical 492 
control points to reduce resistance emergence, in tandem with the discovery of the 493 
relevant resistance mechanisms and the search for new drug therapies. These 494 
combined approaches span from the individual scientific researcher to clinician, to 495 
health agency, to government and population, which must be well-integrated, and alert, 496 
with effective and rapid communication between distinct levels to allow appropriate 497 
responses to be put into action if needed.  498 
Fortunately, whilst drug resistance is emerging in many eukaryotic microbial 499 
pathogens, new tools and methodologies are being developed to (i) predict resistance 500 
mechanisms, (ii) to identify modes of drug action and potential escape pathways  and 501 
(iii) to understand pathogen biochemistry as a means to discover new potential 502 
therapies. With respect to drug resistance, the advent of cost-effective and rapid 503 
genome resequencing allows signatures of selection to be identified103-106, whilst 504 
genome-wide RNAi screens allow the mapping of resistance pathways107,108, and 505 
overexpression libraries109 can assist with drug target deconvolution through selective 506 
screens. These genetic tools are complemented by improvements in proteomics such 507 
that adaptations accompanying drug resistance can be pinpointed, providing 508 
information on resistance mechanisms, and potential diagnostic tools to detect 509 
resistance emergence110.  Combined with the improved sensitivity and resolution of 510 
metabolomics analysis111, biochemical pathways can also be mapped in the context of 511 
drug exposure, allowing bypass mechanisms to be highlighted, if present. These each 512 
provide the essential early warning systems necessary to identify and combat the 513 
spread of drug resistance.  Furthermore, certain combination therapies might offer 514 
novel transmission blocking strategies: very recently resistance to the antimalarial 515 
atovaquone, a component (with proguanil) of the widely used and successful treatment 516 
marketed as Malarone, has been further characterised.  Resistance mutations that 517 
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appear during the target blood stage infection localise to the mitochondrial protein 518 
cytochrome b, one of the few proteins encoded by the highly reduced Plasmodium 519 
mitochondrial genome.  All atovaquone resistance mutations examined generate a 520 
deficient mitochondrion and a parasite that, whilst viable in the blood, is incapable of 521 
development in the mosquito and thereby cannot be transmitted112.  Thus despite the 522 
fact that resistance to atovaquone might arise repeatedly, each incident is isolated.  523 
Drugs that target cytochrome b could form part of combination therapies that are self-524 
limiting in terms of spread of drug resistance and may delay any transmission of 525 
resistance that arises to the drug it is partnered with.  526 
 527 
Concluding remarks 528 
 529 
Drug resistance in eukaryotic microbes is an increasing global problem that threatens 530 
the advances in healthcare over the last 50 years. This mirrors the situation for 531 
bacterial and viral pathogens but is particularly acute given the abundance of 532 
eukaryotic pathogens in the poorest regions of the world. These countries have the 533 
least capacity to respond to resistance emergence through the development of new 534 
drugs vaccines and diagnostics, whilst developed countries lack financial incentives to 535 
assist. Nonetheless, there are opportunities to respond to this threat due to the distinct 536 
biology of many major eukaryotic pathogens and the discoveries made in basic 537 
research focused on their biology. Furthermore, many eukaryotic microbes are 538 
arthropod-borne diseases, such that targeting transmission can be a route to pathogen 539 
control not available for opportunistic pathogens. This can take the form of 540 
transmission-blocking vaccines or drugs targeting Plasmodium113 or the application of 541 
vector control measures such as insecticide impregnated bed nets114, peri-domestic 542 
and indoor residual insecticide spraying114,115, tsetse traps116, or improved housing117. 543 
Sterile insect release is also a route to limiting the vector population and so restricting 544 
disease spread118,119. Eukaryotic microbes have also, like some bacterial pathogens, 545 
been found to show co-operative and social behaviours to optimise their establishment 546 
and transmission in their hosts or vectors120,121.  These social responses can control 547 
parasite density or the development of transmission stages122-124, such that blocking or 548 
mimicking signals for communication or their transduction pathways provides new 549 
routes to limit the impact of the pathogens using strategies that might be less 550 
susceptible to resistance emergence. 551 
Whether or not new targets or new approaches can be identified, there is a real 552 
need to optimise the delivery and deployment of drugs.  Control of drug quality, 553 
distribution and supply of cost-effective drugs is crucial.  Also the application of both 554 
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epidemiological modelling and evolutionary theory to guide drug treatment policies is 555 
important in prolonging the life span of drugs and thereby maximising the return on the 556 
considerable cost associated with developing and introducing a new drug.  Targeted 557 
therapy as opposed to mass drug administration is key to limiting the emergence of 558 
resistance, or containing resistance when it is detected. This requires an integration of 559 
epidemiology, diagnosis, detection and supply chain control as well as investment in a 560 
pipeline of new therapeutics ready to be deployed when resistance inevitably emerges.  561 
Only through slowing resistance emergence and accelerating new drug discovery will 562 
the control successes achieved against eukaryotic microbial pathogens be sustained. 563 
  564 
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Table 1.   565 
Diseases caused by eukaryotic microbes, their vectors and front-line treatment 566 
options. Several of the parasitic pathogens are arthropod-transmitted, and in these 567 
cases the responsible vector is shown. Fungal pathogens are predominantly 568 
opportunistic. 569 
 570 
Table 2 571 
Modes of action and mechanisms of drug resistance in eukaryotic microbes 572 
 573 
Figure Legends 574 
 575 
Figure 1 Timelines for emergence of drug resistance in parasitic diseases (A) 576 
and Fungi (B). The darker bar represents the time from first widespread clinical use 577 
to the first year drug resistance was suspected or confirmed.  The shading indicates 578 
that certain drugs are still in use for particular indications or in specific geographical 579 
locations. Abbreviations: S-P, sulfadoxine-pyrimethamine; PPQ, piperaquine; ACTs, 580 
artemisinin combination therapies; NECT, nifurtimox eflornithine combination therapy; 581 
L-AMB, liposomal amphotericin B; MLT, miltefosine. For fungal pathogens, insensitive 582 
or resistant strains have been identified shortly after the introduction of all of the major 583 
classes of antifungal agents.  In the case of amphotericin B, there remains very little 584 
resistance – and differences in sensitivity mainly reflect the relative inherent sensitivity 585 
of different species to this agent. 586 
 587 
 588 
Figure 2 Molecular mechanisms of drug-resistance.  589 
Eukaryotic microbial pathogens can exhibit drug resistance through reducing the 590 
overall intracellular concentration of the drug (less uptake, more efflux), by inactivating 591 
or failing to activate the drug, or by sequestering the drug away from its target. 592 
Resistance can also be mediated by reducing affinity of the drug for the target by 593 
mutation or by reducing the drug effect by overexpression of the target. Salvage and 594 
by-pass pathways can also lower the overall impact of the drug action, as can the 595 
activation of pathways in order to repair any damage caused. 596 
  597 
 18 
 598 
Reference List 599 
 600 
1.  Woolhouse, M. & Farrar, J. Policy: An intergovernmental panel on antimicrobial 601 
resistance. Nature 509, 555-557 (2014). 602 
2.  Lutje, V., Seixas, J., & Kennedy, A. Chemotherapy for second-stage human 603 
African trypanosomiasis. Cochrane. Database. Syst. Rev. 6, CD006201 604 
(2013). 605 
3.  Fernandez, F. M., Green, M. D., & Newton, P. N. Prevalence and detection of 606 
counterfeit pharmaceuticals: A mini review. Industrial & Engineering 607 
Chemistry Research 47, 585-590 (2008). 608 
4.  Nayyar, G. M., Breman, J. G., Newton, P. N., & Herrington, J. Poor-quality 609 
antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet 610 
Infect. Dis. 12, 488-496 (2012). 611 
5.  Verweij, P. E., Chowdhary, A., Melchers, W. J., & Meis, J. F. Azole resistance in 612 
Aspergillus fumigatus: can we retain the clinical use of mold-active 613 
antifungal azoles? Clin. Infect. Dis. 62, 362-368 (2016). 614 
6.  Woolhouse, M., Ward, M., van, B. B., & Farrar, J. Antimicrobial resistance in 615 
humans, livestock and the wider environment. Philos. Trans. R. Soc. 616 
Lond B Biol. Sci. 370, 20140083 (2015). 617 
7.  Lewis, K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 618 
5, 48-56 (2007). 619 
8.  Cohen, N. R., Lobritz, M. A., & Collins, J. J. Microbial persistence and the road 620 
to drug resistance. Cell Host. Microbe 13, 632-642 (2013). 621 
9.  LaFleur, M. D., Kumamoto, C. A., & Lewis, K. Candida albicans biofilms produce 622 
antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50, 623 
3839-3846 (2006). 624 
10.  Kucharikova, S., Tournu, H., Lagrou, K., Van, D. P., & Bujdakova, H. Detailed 625 
comparison of Candida albicans and Candida glabrata biofilms under 626 
different conditions and their susceptibility to caspofungin and 627 
anidulafungin. J. Med. Microbiol. 60, 1261-1269 (2011). 628 
11.  LaFleur, M. D., Qi, Q., & Lewis, K. Patients with long-term oral carriage harbor 629 
high-persister mutants of Candida albicans. Antimicrob. Agents 630 
Chemother. 54, 39-44 (2010). 631 
12.  Kussell, E., Kishony, R., Balaban, N. Q., & Leibler, S. Bacterial persistence: a 632 
model of survival in changing environments. Genetics 169, 1807-1814 633 
(2005). 634 
13.  Rovira-Graells, N., et al. Transcriptional variation in the malaria parasite 635 
Plasmodium falciparum. Genome Res. 22, 925-938 (2012). 636 
14.  Keren, I., Kaldalu, N., Spoering, A., Wang, Y., & Lewis, K. Persister cells and 637 
tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13-18 (2004). 638 
 19 
15.  Pankey, G. A. & Sabath, L. D. Clinical relevance of bacteriostatic versus 639 
bactericidal mechanisms of action in the treatment of Gram-positive 640 
bacterial infections. Clin. Infect. Dis. 38, 864-870 (2004). 641 
16.  Laufer, M. K., Djimde, A. A., & Plowe, C. V. Monitoring and deterring drug-642 
resistant malaria in the era of combination therapy. Am. J. Trop. Med. 643 
Hyg. 77, 160-169 (2007). 644 
17.  Peters, W. The prevention of antimalarial drug resistance. Pharmacol. Ther. 47, 645 
499-508 (1990). 646 
18.  White, N. J. & Olliaro, P. L. Strategies for the prevention of antimalarial drug 647 
resistance: Rationale for combination chemotherapy for malaria. 648 
Parasitol. Today 12, 399-401 (1996). 649 
19.  Priotto, G., et al. Nifurtimox-eflornithine combination therapy for second-stage 650 
African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, 651 
randomised, phase III, non-inferiority trial. Lancet 374, 56-64 (2009). 652 
20.  Nosten, F. & White, N. J. Artemisinin-based combination treatment of falciparum 653 
malaria. Am. J. Trop. Med. Hyg. 77, 181-192 (2007). 654 
21.  Hotez, P. J., Bottazzi, M. E., & Strych, U. New vaccines for the world's poorest 655 
people. Annu. Rev. Med.  (2015). 656 
22.  Kumar, R. & Engwerda, C. Vaccines to prevent leishmaniasis. Clin. Transl. 657 
Immunology 3, e13 (2014). 658 
23.  Cassone, A. Development of vaccines for Candida albicans: fighting a skilled 659 
transformer. Nat. Rev. Microbiol. 11, 884-891 (2013). 660 
24.  Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. J. Infect. Dis 184, 661 
770-776 (2001). 662 
25.  Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H., & Meshnick, S. R. 663 
Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209-218 664 
(2002). 665 
26.  Awasthi, G. & Das, A. Genetics of chloroquine-resistant malaria: a haplotypic 666 
view. Mem. Inst. Oswaldo Cruz 108, 947-961 (2013). 667 
27.  Fidock, D. A., et al. Mutations in the P-falciparum digestive vacuole 668 
transmembrane protein PfCRT and evidence for their role in chloroquine 669 
resistance. Mol. Cell 6, 861-871 (2000). 670 
28.  Pulcini, S., et al. Mutations in the Plasmodium falciparum chloroquine resistance 671 
transporter, PfCRT, enlarge the parasite's food vacuole and alter drug 672 
sensitivities. Sci. Rep. 5, 14552 (2015). 673 
29.  Noedl, H., et al. Evidence of artemisinin-resistant malaria in western Cambodia. 674 
N. Engl. J. Med. 359, 2619-2620 (2008). 675 
30.  Amaratunga, C., et al. Artemisinin-resistant Plasmodium falciparum in Pursat 676 
province, western Cambodia: a parasite clearance rate study. Lancet 677 
Infect. Dis. 12, 851-858 (2012). 678 
 20 
31.  Dondorp, A. M., et al. Artemisinin resistance in Plasmodium falciparum malaria. 679 
N. Engl. J. Med. 361, 455-467 (2009). 680 
32.  Mok, S., et al. Drug resistance. Population transcriptomics of human malaria 681 
parasites reveals the mechanism of artemisinin resistance. Science 347, 682 
431-435 (2015). 683 
33.  Miotto, O., et al. Multiple populations of artemisinin-resistant Plasmodium 684 
falciparum in Cambodia. Nat. Genet. 45, 648-655 (2013). 685 
34.  Takala-Harrison, S., et al. Genetic loci associated with delayed clearance of 686 
Plasmodium falciparum following artemisinin treatment in Southeast 687 
Asia. Proc. Natl. Acad. Sci. U. S. A 110, 240-245 (2013). 688 
35.  Ariey, F., et al. A molecular marker of artemisinin-resistant Plasmodium 689 
falciparum malaria. Nature 505, 50-55 (2014). 690 
36.  Ghorbal, M., et al. Genome editing in the human malaria parasite Plasmodium 691 
falciparum using the CRISPR-Cas9 system. Nat. Biotechnol. 32, 819-821 692 
(2014). 693 
37.  Straimer, J., et al. Drug resistance. K13-propeller mutations confer artemisinin 694 
resistance in Plasmodium falciparum clinical isolates. Science 347, 428-695 
431 (2015). 696 
38.  MalariaGEN Plasmodium falciparum Community Project Genomic epidemiology 697 
of artemisinin resistant malaria. eLife 5 (2016). 698 
39.  Mbengue, A., et al. A molecular mechanism of artemisinin resistance in 699 
Plasmodium falciparum malaria. Nature 520, 683-687 (2015). 700 
40.  Gabryszewski, S. J., Modchang, C., Musset, L., Chookajorn, T., & Fidock, D. A. 701 
Combinatorial genetic modeling of pfcrt-mediated drug resistance 702 
evolution in Plasmodium falciparum. Mol. Biol. Evol.  (2016). 703 
41.  Sisowath, C., et al. In vivo selection of Plasmodium falciparum parasites carrying 704 
the chloroquine-susceptible pfcrt K76 allele after treatment with 705 
artemether-lumefantrine in Africa. J. Infect. Dis 199, 750-757 (2009). 706 
42.  Venkatesan, M., et al. Polymorphisms in Plasmodium falciparum chloroquine 707 
resistance transporter and multidrug resistance 1 genes: parasite risk 708 
factors that affect treatment outcomes for P. falciparum malaria after 709 
artemether-lumefantrine and artesunate-amodiaquine. Am. J. Trop. Med. 710 
Hyg. 91, 833-843 (2014). 711 
43.  Amaratunga, C., et al. Dihydroartemisinin-piperaquine resistance in Plasmodium 712 
falciparum malaria in Cambodia: a multisite prospective cohort study. 713 
Lancet Infect. Dis. 16, 357-365 (2016). 714 
44.  Franco, J. R., Simarro, P. P., Diarra, A., Ruiz-Postigo, J. A., & Jannin, J. G. The 715 
journey towards elimination of gambiense human African 716 
trypanosomiasis: not far, nor easy. Parasitology 141, 748-760 (2014). 717 
45.  Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T., & Cerami, A. 718 
Trypanothione:  a novel bis(glutathionyl)spermidine cofactor for 719 
 21 
glutathione reductase in trypanosomatids. Science 227, 1485-1487 720 
(1985). 721 
46.  Fairlamb, A. H., Henderson, G. B., & Cerami, A. Trypanothione is the primary 722 
target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. 723 
Sci. USA 86, 2607-2611 (1989). 724 
47.  Matovu, E., et al. Melarsoprol refractory T.b. gambiense from Omugo, north-725 
western Uganda. Trop. Med. Int. Health 6, 407-411 (2001). 726 
48.  Robays, J., et al. High failure rates of melarsoprol for sleeping sickness, 727 
Democratic Republic of Congo. Emerg. Infect. Dis. 14, 966-967 (2008). 728 
49.  Munday, J. C., et al. Trypanosoma brucei aquaglyceroporin 2 is a high-affinity 729 
transporter for pentamidine and melaminophenyl arsenic drugs and the 730 
main genetic determinant of resistance to these drugs. J. Antimicrob. 731 
Chemother. 69, 651-663 (2014). 732 
50.  Song, J., et al. Pentamidine is not a permeant but a nanomolar inhibitor of the 733 
Trypanosoma brucei aquaglyceroporin-2. PLoS Pathog. 12, e1005436 734 
(2016). 735 
51.  Urbina, J. A. & Docampo, R. Specific chemotherapy of Chagas disease: 736 
controversies and advances. Trends Parasitol. 19, 495-501 (2003). 737 
52.  Molina, I., et al. Randomized trial of posaconazole and benznidazole for chronic 738 
Chagas' disease. N. Engl. J. Med. 370, 1899-1908 (2014). 739 
53.  Morillo, C. A., et al. Randomized trial of benznidazole for chronic Chagas' 740 
cardiomyopathy. N. Engl. J. Med. 373, 1295-1306 (2015). 741 
54.  Chatelain, E. Chagas disease drug discovery: toward a new era. J. Biomol. 742 
Screen. 20, 22-35 (2015). 743 
55.  Urbina, J. A. Recent clinical trials for the etiological treatment of chronic chagas 744 
disease: advances, challenges and perspectives. J. Euk. Microbiol. 62, 745 
149-156 (2015). 746 
56.  McGwire, B. S. & Satoskar, A. R. Leishmaniasis: clinical syndromes and 747 
treatment. QJM. 107, 7-14 (2014). 748 
57.  Sundar, S. & Chakravarty, J. An update on pharmacotherapy for leishmaniasis. 749 
Expert Opin. Pharmacother. 16, 237-252 (2015). 750 
58.  World Health Organization, Control of the Leishmaniases,in  949 ed.(World 751 
Health Organization, Geneva, 2010), pp.1-186. 752 
59.  Olliaro, P. L., et al. Treatment options for visceral leishmaniasis: a systematic 753 
review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5, 754 
763-774 (2005). 755 
60.  Perry, M. R., et al. Visceral leishmaniasis and arsenic: an ancient poison 756 
contributing to antimonial treatment failure in the Indian subcontinent? 757 
PLoS Negl. Trop. Dis. 5, e1227 (2011). 758 
 22 
61.  Dey, S., et al. High level arsenite resistance in Leishmania tarentolae is mediated 759 
by an active extrusion system. Mol. Biochem. Parasitol. 67, 49-57 (1994). 760 
62.  Perry, M. R., Wyllie, S., Raab, A., Feldmann, J., & Fairlamb, A. H. Chronic 761 
exposure to arsenic in drinking water can lead to resistance to antimonial 762 
drugs in a mouse model of visceral leishmaniasis. Proc. Natl. Acad. Sci. 763 
USA 110, 19932-19937 (2013). 764 
63.  Perry, M. R., et al. Arsenic exposure and outcomes of antimonial treatment in 765 
visceral leishmaniasis patients in Bihar, India: a retrospective cohort 766 
study. PLoS Negl. Trop. Dis. 9, e0003518 (2015). 767 
64.  Shaked-Mishan, P., Ulrich, N., Ephros, M., & Zilberstein, D. Novel intracellular 768 
Sb-V reducing activity correlates with antimony susceptibility in 769 
Leishmania donovani. J. Biol. Chem. 276, 3971-3976 (2001). 770 
65.  Decuypere, S., et al. Gene expression analysis of the mechanism of natural 771 
Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob. 772 
Agents Chemother. 49, 4616-4621 (2005). 773 
66.  Decuypere, S., et al. Molecular mechanisms of drug resistance in natural 774 
Leishmania populations vary with genetic background. PLoS Negl. Trop. 775 
Dis. 6, e1514 (2012). 776 
67.  Brotherton, M. C., et al. Proteomic and genomic analyses of antimony resistant 777 
Leishmania infantum mutant. J. Parasitol. Res. 8, e81899 (2013). 778 
68.  Biyani, N., Singh, A. K., Mandal, S., Chawla, B., & Madhubala, R. Differential 779 
expression of proteins in antimony-susceptible and -resistant isolates of 780 
Leishmania donovani. Mol. Biochem. Parasitol. 179, 91-99 (2011). 781 
69.  Fyfe, P. K., Westrop, G. D., Silva, A. M., Coombs, G. H., & Hunter, W. N. 782 
Leishmania TDR1 structure, a unique trimeric glutathione transferase 783 
capable of deglutathionylation and antimonial prodrug activation. Proc. 784 
Natl. Acad. Sci. USA 109, 11693-11698 (2012). 785 
70.  Zhou, Y., Messier, N., Ouellette, M., Rosen, B. P., & Mukhopadhyay, R. 786 
Leishmania major LmACR2 is a pentavalent antimony reductase that 787 
confers sensitivity to the drug Pentostam. J. Biol. Chem. 279, 37445-788 
37451 (2004). 789 
71.  Plourde, M., et al. Generation of an aquaglyceroporin AQP1 null mutant in 790 
Leishmania major. Mol. Biochem. Parasitol. 201, 108-111 (2015). 791 
72.  Marquis, N., Gourbal, B., Rosen, B. P., Mukhopadhyay, R., & Ouellette, M. 792 
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-793 
resistant Leishmania. Mol. Microbiol. 57, 1690-1699 (2005). 794 
73.  Gourbal, B., et al. Drug uptake and modulation of drug resistance in Leishmania 795 
by an aquaglyceroporin. J. Biol. Chem. 279, 31010-31017 (2004). 796 
74.  Mandal, S., Maharjan, M., Singh, S., Chatterjee, M., & Madhubala, R. Assessing 797 
aquaglyceroporin gene status and expression profile in antimony-798 
susceptible and -resistant clinical isolates of Leishmania donovani from 799 
India. J. Antimicrob. Chemother. 65, 496-507 (2010). 800 
 23 
75.  Maharjan, M., Singh, S., Chatterjee, M., & Madhubala, R. Role of 801 
aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant 802 
clinical isolates of Leishmania donovani. Am. J. Trop. Med. Hyg. 79, 69-803 
75 (2008). 804 
76.  Rogers, M. B., et al. Chromosome and gene copy number variation allow major 805 
structural change between species and strains of Leishmania. Genome 806 
Res. 21, 2129-2142 (2011). 807 
77.  Sterkers, Y., Crobu, L., Lachaud, L., Pages, M., & Bastien, P. Parasexuality and 808 
mosaic aneuploidy in Leishmania: alternative genetics. Trends Parasitol. 809 
30, 429-435 (2014). 810 
78.  Rojo, D., et al. A multiplatform metabolomic approach to the basis of antimonial 811 
action and resistance in Leishmania infantum. J. Parasitol. Res. 10, 812 
e0130675 (2015). 813 
79.  Berg, M., et al. Metabolic adaptations of Leishmania donovani in relation to 814 
differentiation, drug resistance, and drug pressure. Mol. Microbiol. 90, 815 
428-442 (2013). 816 
80.  Dey, S., Ouellette, M., Lightbody, J., Papadopoulou, B., & Rosen, B. P. An ATP-817 
dependent As(III)-glutathione transport system in membrane vesicles of 818 
Leishmania tarentolae. Proc. Natl. Acad. Sci. USA 93, 2192-2197 (1996). 819 
81.  Manzano, J. I., Garcia-Hernandez, R., Castanys, S., & Gamarro, F. A new ABC 820 
half-transporter in Leishmania major is involved in resistance to antimony. 821 
Antimicrob. Agents Chemother. 57, 3719-3730 (2013). 822 
82.  Sundar, S., et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis 823 
in India after a decade of use. Clin. Infect. Dis. 55, 543-550 (2012). 824 
83.  Rijal, S., et al. Increasing failure of miltefosine in the treatment of Kala-azar in 825 
Nepal and the potential role of parasite drug resistance, reinfection, or 826 
noncompliance. Clin. Infect. Dis. 56, 1530-1538 (2013). 827 
84.  Seifert, K., et al. Characterisation of Leishmania donovani promastigotes 828 
resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Ag. 829 
22, 380-387 (2003). 830 
85.  Kulshrestha, A., Sharma, V., Singh, R., & Salotra, P. Comparative transcript 831 
expression analysis of miltefosine-sensitive and miltefosine-resistant 832 
Leishmania donovani. Parasitol. Res. 113, 1171-1184 (2014). 833 
86.  Perlin, D. S., Shor, E., & Zhao, Y. Update on Antifungal Drug Resistance. Curr. 834 
Clin. Microbiol. Rep. 2, 84-95 (2015). 835 
87.  Denning, D. W. & Bromley, M. J. Infectious Disease. How to bolster the antifungal 836 
pipeline. Science 347, 1414-1416 (2015). 837 
88.  Epaulard, O., et al. A multistep voriconazole-related phototoxic pathway may 838 
lead to skin carcinoma: results from a French nationwide study. Clin. 839 
Infect. Dis. 57, e182-e188 (2013). 840 
 24 
89.  Shor, E. & Perlin, D. S. Coping with stress and the emergence of multidrug 841 
resistance in fungi. PLoS Pathog. 11, e1004668 (2015). 842 
90.  Kidd, S. E., Goeman, E., Meis, J. F., Slavin, M. A., & Verweij, P. E. Multi-triazole-843 
resistant Aspergillus fumigatus infections in Australia. Mycoses 58, 350-844 
355 (2015). 845 
91.  van der Linden, J. W., et al. Prospective multicenter international surveillance of 846 
azole resistance in Aspergillus fumigatus. Emerg. Infect. Dis 21, 1041-847 
1044 (2015). 848 
92.  Wang, E., et al. The ever-evolving landscape of candidaemia in patients with 849 
acute leukaemia: non-susceptibility to caspofungin and multidrug 850 
resistance are associated with increased mortality. J. Antimicrob. 851 
Chemother. 70, 2362-2368 (2015). 852 
93.  Chowdhary, A., Kathuria, S., Xu, J., & Meis, J. F. Emergence of azole-resistant 853 
Aspergillus fumigatus strains due to agricultural azole use creates an 854 
increasing threat to human health. PLoS Pathog. 9, e1003633 (2013). 855 
94.  Vermeulen, E., Lagrou, K., & Verweij, P. E. Azole resistance in Aspergillus 856 
fumigatus: a growing public health concern. Curr. Opin. Infect. Dis 26, 857 
493-500 (2013). 858 
95.  Snelders, E., et al. Triazole fungicides can induce cross-resistance to medical 859 
triazoles in Aspergillus fumigatus. J. Parasitol. Res. 7, e31801 (2012). 860 
96.  Snelders, E., Melchers, W. J., & Verweij, P. E. Azole resistance in Aspergillus 861 
fumigatus: a new challenge in the management of invasive aspergillosis? 862 
Future. Microbiol. 6, 335-347 (2011). 863 
97.  Abdolrasouli, A., et al. Genomic context of azole resistance mutations in 864 
Aspergillus fumigatus determined using whole-genome sequencing. 865 
mBio. 6, e00536 (2015). 866 
98.  Katiyar, S. K., et al. Fks1 and Fks2 are functionally redundant but differentially 867 
regulated in Candida glabrata: implications for echinocandin resistance. 868 
Antimicrob. Agents Chemother. 56, 6304-6309 (2012). 869 
99.  Singh, S. D., et al. Hsp90 governs echinocandin resistance in the pathogenic 870 
yeast Candida albicans via calcineurin. PLoS Pathog. 5, e1000532 871 
(2009). 872 
100.  Pfaller, M. A. & Diekema, D. J. Progress in antifungal susceptibility testing of 873 
Candida spp. by use of Clinical and Laboratory Standards Institute broth 874 
microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50, 2846-2856 875 
(2012). 876 
101.  Alexander, B. D., et al. Increasing echinocandin resistance in Candida glabrata: 877 
clinical failure correlates with presence of FKS mutations and elevated 878 
minimum inhibitory concentrations. Clin. Infect. Dis. 56, 1724-1732 879 
(2013). 880 
102.  Denoeud-Ndam, L., et al. A multi-center, open-label trial to compare the efficacy 881 
and pharmacokinetics of Artemether-Lumefantrine in children with severe 882 
 25 
acute malnutrition versus children without severe acute malnutrition: 883 
study protocol for the MAL-NUT study. BMC Infect. Dis 15, 228 (2015). 884 
103.  Kinga, M. K., et al. Quantitative genome re-sequencing defines multiple 885 
mutations conferring chloroquine resistance in rodent malaria. BMC 886 
Genomics 13, 106 (2012). 887 
104.  Manske, M., et al. Analysis of Plasmodium falciparum diversity in natural 888 
infections by deep sequencing. Nature 487, 375-379 (2012). 889 
105.  Cheeseman, I. H., et al. A major genome region underlying artemisinin resistance 890 
in malaria. Science 336, 79-82 (2012). 891 
106.  Yuan, J., et al. Chemical genomic profiling for antimalarial therapies, response 892 
signatures, and molecular targets. Science 333, 724-729 (2011). 893 
107.  Glover, L., et al. Genome-scale RNAi screens for high-throughput phenotyping 894 
in bloodstream-form African trypanosomes. Nat. Protoc. 10, 106-133 895 
(2015). 896 
108.  Alsford, S., et al. High-throughput decoding of antitrypanosomal drug efficacy 897 
and resistance. Nature 482, 232-236 (2012). 898 
109.  Begolo, D., Erben, E., & Clayton, C. Drug target identification using a 899 
trypanosome overexpression library. Antimicrob. Agents Chemother. 58, 900 
6260-6264 (2014). 901 
110.  Cowman, A. F. Functional analysis of drug resistance in Plasmodium falciparum 902 
in the post-genomic era. Int. J. Parasitol. 31, 871-878 (2001). 903 
111.  Vincent, I. M. & Barrett, M. P. Metabolomic-based strategies for anti-parasite 904 
drug discovery. J. Biomol. Screen. 20, 44-55 (2015). 905 
112.  Goodman, C. D., et al. Parasites resistant to the antimalarial atovaquone fail to 906 
transmit by mosquitoes. Science 352, 349-353 (2016). 907 
113.  Guttery, D. S., Roques, M., Holder, A. A., & Tewari, R. Commit and transmit: 908 
molecular players in Plasmodium sexual development and zygote 909 
differentiation. Trends Parasitol. 31, 676-685 (2015). 910 
114.  Hemingway, J. The role of vector control in stopping the transmission of malaria: 911 
threats and opportunities. Philos. Trans. R. Soc. Lond B Biol. Sci. 369, 912 
20130431 (2014). 913 
115.  Dias, J. C. Southern Cone Initiative for the elimination of domestic populations of 914 
Triatoma infestans and the interruption of transfusional Chagas disease. 915 
Historical aspects, present situation, and perspectives. Mem. Inst. 916 
Oswaldo Cruz 102 Suppl 1, 11-18 (2007). 917 
116.  Welburn, S. C. & Maudlin, I. Priorities for the elimination of sleeping sickness. 918 
Adv. Parasitol. 79, 299-337 (2012). 919 
117.  Dias, J. C., Silveira, A. C., & Schofield, C. J. The impact of Chagas disease 920 
control in Latin America: a review. Mem. Inst. Oswaldo Cruz 97, 603-612 921 
(2002). 922 
 26 
118.  Abd-Alla, A. M., et al. Improving Sterile Insect Technique (SIT) for tsetse flies 923 
through research on their symbionts and pathogens. J. Invertebr. Pathol. 924 
112 Suppl, S2-10 (2013). 925 
119.  Oliva, C. F., et al. Current status and future challenges for controlling malaria with 926 
the sterile insect technique: technical and social perspectives. Acta Trop. 927 
132 Suppl, S130-S139 (2014). 928 
120.  Dantzler, K. W., Ravel, D. B., Brancucci, N. M., & Marti, M. Ensuring transmission 929 
through dynamic host environments: host-pathogen interactions in 930 
Plasmodium sexual development. Curr. Opin. Microbiol. 26, 17-23 931 
(2015). 932 
121.  Imhof, S. & Roditi, I. The social life of African trypanosomes. Trends Parasitol. 933 
31, 490-498 (2015). 934 
122.  Mony, B. M., et al. Genome-wide dissection of the quorum sensing signalling 935 
pathway in Trypanosoma brucei. Nature 505, 681-685 (2014). 936 
123.  Mantel, P. Y., et al. Malaria-infected erythrocyte-derived microvesicles mediate 937 
cellular communication within the parasite population and with the host 938 
immune system. Cell Host. Microbe 13, 521-534 (2013). 939 
124.  Regev-Rudzki, N., et al. Cell-cell communication between malaria-infected red 940 
blood cells via exosome-like vesicles. Cell 153, 1120-1133 (2013). 941 
125.  WHO, Guidelines for the Treatment of Malaria. Third Edition,in (World Health 942 
Organisation, 2015), pp.1-316. 943 
126.  WHO, WHO Model List of Essential Medicines, 19th Edition,in (WHO, 2015), 944 
pp.1-51. 945 
127.  WHO, Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal 946 
Disease in HIV-Infected Adults, Adolescents and Children,in (WHO 947 
Document Production Servies, Geneva, 2011), pp.1-37. 948 
128.  Leroux, S. & Ullmann, A. J. Management and diagnostic guidelines for fungal 949 
diseases in infectious diseases and clinical microbiology: critical 950 
appraisal. Clin. Microbiol. Infect. 19, 1115-1121 (2013). 951 
129.  Kullberg, B. J. & Arendrup, M. C. Invasive Candidiasis. N. Engl. J. Med. 373, 952 
1445-1456 (2015). 953 
130.  Ecker, A., Lehane, A. M., Clain, J., & Fidock, D. A. PfCRT and its role in 954 
antimalarial drug resistance. Trends Parasitol. 28, 504-514 (2012). 955 
131.  Wootton, J. C., et al. Genetic diversity and chloroquine selective sweeps in 956 
Plasmodium falciparum. Nature 418, 320-323 (2002). 957 
132.  Sanchez, C. P., Stein, W., & Lanzer, M. Trans stimulation provides evidence for 958 
a drug efflux carrier as the mechanism of chloroquine resistance in 959 
Plasmodium falciparum. Biochemistry 42, 9383-9394 (2003). 960 
 27 
133.  Sanchez, C. P., Dave, A., Stein, W. D., & Lanzer, M. Transporters as mediators 961 
of drug resistance in Plasmodium falciparum. Int. J. Parasitol. 40, 1109-962 
1118 (2010). 963 
134.  Ferdig, M. T., et al. Dissecting the loci of low-level quinine resistance in malaria 964 
parasites. Mol. Microbiol. 52, 985-997 (2004). 965 
135.  Valderramos, S. G., et al. Identification of a mutant PfCRT-mediated chloroquine 966 
tolerance phenotype in Plasmodium falciparum. PLoS Pathog. 6, 967 
e1000887 (2010). 968 
136.  Pelleau, S., et al. Adaptive evolution of malaria parasites in French Guiana: 969 
Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. 970 
Proc. Natl. Acad. Sci. U. S. A 112, 11672-11677 (2015). 971 
137.  Wellems, T. E., Walker-Jonah, A., & Panton, L. J. Genetic mapping of the 972 
chloroquine-resistance locus on Plasmodium falciparum chromosome 7. 973 
Proc. Natl. Acad. Sci. U. S. A 88, 3382-3386 (1991). 974 
138.  Duraisingh, M. T., et al. Linkage disequilibrium between two chromosomally 975 
distinct loci associated with increased resistance to chloroquine in 976 
Plasmodium falciparum. Parasitology 121, 1-7 (2000). 977 
139.  Meshnick, S. R., Taylor, T. E., & Kamchonwongpaisan, S. Artemisinin and the 978 
antimalarial endoperoxides - from herbal remedy to targeted 979 
chemotherapy. Microbiol. Rev. 60, 301 (1996). 980 
140.  Wang, P., Read, M., Sims, P. F. G., & Hyde, J. E. Sulfadoxine resistance in the 981 
human malaria parasite Plasmodium falciparum is determined by 982 
mutations in dihydropteroate synthetase and an additional factor 983 
associated with folate utilization. Mol. Microbiol. 23, 979-986 (1997). 984 
141.  Heinberg, A. & Kirkman, L. The molecular basis of antifolate resistance in 985 
Plasmodium falciparum: looking beyond point mutations. Ann. N. Y. 986 
Acad. Sci. 1342, 10-18 (2015). 987 
142.  A. F. Cowman, "The Molecular Basis of Resistance to the Sulfones, 988 
Sulfonamides, and Dihydrofolate Reductase Inhibitors,"in Malaria: 989 
Parasite Biology,Pathogenesis, and Protection, edited by Irwin W. 990 
Sherman 1998), pp.317-330. 991 
143.  Rose, G. W., Suh, K. N., Kain, K. C., Le, S. N., & McCarthy, A. E. Atovaquone-992 
proguanil resistance in imported falciparum malaria in a young child. 993 
Pediatr. Infect. Dis J. 27, 567-569 (2008). 994 
144.  Carter, N. S. & Fairlamb, A. H. Arsenical-resistant trypanosomes lack an unusual 995 
adenosine transporter. Nature 361, 173-176 (1993). 996 
145.  Maser, P., Sutterlin, C., Kralli, A., & Kaminsky, R. A nucleoside transporter from 997 
Trypanosoma brucei involved in drug resistance. Science 285, 242-244 998 
(1999). 999 
146.  Baker, N., et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and 1000 
pentamidine in African trypanosomes. Proc. Natl. Acad. Sci. U. S. A 109, 1001 
10996-11001 (2012). 1002 
 28 
147.  Graf, F. E., et al. Chimerization at the AQP2-AQP3 locus is the genetic basis of 1003 
melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei 1004 
gambiense isolates. Int. J. Parasitol. Drugs Drug Resist. 5, 65-68 (2015). 1005 
148.  Pyana, P. P., et al. Melarsoprol sensitivity profile of Trypanosoma brucei 1006 
gambiense isolates from cured and relapsed sleeping sickness patients 1007 
from the Democratic Republic of the Congo. PLoS Negl. Trop. Dis. 8, 1008 
e3212 (2014). 1009 
149.  Graf, F. E., et al. Aquaporin 2 mutations in Trypanosoma brucei gambiense field 1010 
isolates correlate with decreased susceptibility to pentamidine and 1011 
melarsoprol. PLoS Negl. Trop. Dis. 7, e2475 (2013). 1012 
150.  Kazibwe, A. J., et al. Genotypic status of the TbAT1/P2 adenosine transporter of 1013 
Trypanosoma brucei gambiense isolates from Northwestern Uganda 1014 
following melarsoprol withdrawal. PLoS Negl. Trop. Dis. 3, e523 (2009). 1015 
151.  Vincent, I. M., et al. A molecular mechanism for eflornithine resistance in African 1016 
trypanosomes. PLoS Pathog. 6, e1001204 (2010). 1017 
152.  Mathieu, C., et al. Trypanosoma brucei eflornithine transporter AAT6 is a low-1018 
affinity low-selective transporter for neutral amino acids. Biochem. J. 463, 1019 
9-18 (2014). 1020 
153.  Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M., & Cheeseman, I. A 1021 
mechanism for cross-resistance to nifurtimox and benznidazole in 1022 
trypanosomes. Proc. Natl. Acad. Sci. USA 105, 5022-5027 (2008). 1023 
154.  Hall, B. S., Bot, C., & Wilkinson, S. R. Nifurtimox activation by trypanosomal type 1024 
I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 1025 
286, 13088-13095 (2011). 1026 
155.  Patterson, S. & Wyllie, S. Nitro drugs for the treatment of trypanosomatid 1027 
diseases: past, present, and future prospects. Trends Parasitol. 30, 289-1028 
298 (2014). 1029 
156.  Sokolova, A. Y., et al. Cross-resistance to nitro drugs and implications for 1030 
treatment of human African trypanosomiasis. Antimicrob. Agents 1031 
Chemother. 54, 2893-2900 (2010). 1032 
157.  Wyllie, S., et al. Nitroheterocyclic drug resistance mechanisms in Trypanosoma 1033 
brucei. J. Antimicrob. Chemother. 71, 625-634 (2015). 1034 
158.  Mejia, A. M., et al. Benznidazole-resistance in Trypanosoma cruzi is a readily 1035 
acquired trait that can arise independently in a single population. J. Infect. 1036 
Dis. 206, 220-228 (2012). 1037 
159.  Trochine, A., Creek, D. J., Faral-Tello, P., Barrett, M. P., & Robello, C. 1038 
Benznidazole biotransformation and multiple targets in Trypanosoma 1039 
cruzi revealed by metabolomics. PLoS Negl. Trop. Dis. 8, e2844 (2014). 1040 
160.  Hall, B. S. & Wilkinson, S. R. Activation of benznidazole by trypanosomal type I 1041 
nitroreductases results in glyoxal formation. Antimicrob. Agents 1042 
Chemother. 56, 115-123 (2012). 1043 
 29 
161.  Zingales, B., et al. A novel ABCG-like transporter of Trypanosoma cruzi is 1044 
involved in natural resistance to benznidazole. Mem. Inst. Oswaldo Cruz 1045 
110, 433-444 (2015). 1046 
162.  Murta, S. M. F., et al. Deletion of copies of the gene encoding old yellow enzyme 1047 
(TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-1048 
induced benznidazole resistance in Trypanosoma cruzi. Mol. Biochem. 1049 
Parasitol. 146, 151-162 (2006). 1050 
163.  Andrade, H. M., et al. Proteomic analysis of Trypanosoma cruzi resistance to 1051 
benznidazole. J. Proteome Res. 7, 2357-2367 (2008). 1052 
164.  Kubata, B. K., et al. A key role for old yellow enzyme in the metabolism of drugs 1053 
by Trypanosoma cruzi. J. Exp. Med. 196, 1241-1251 (2002). 1054 
165.  Wyllie, S., Cunningham, M. L., & Fairlamb, A. H. Dual action of antimonial drugs 1055 
on thiol redox metabolism in the human pathogen Leishmania donovani. 1056 
J. Biol. Chem. 279, 39925-39932 (2004). 1057 
166.  Baiocco, P., Colotti, G., Franceschini, S., & Ilari, A. Molecular basis of antimony 1058 
treatment in leishmaniasis. J. Med. Chem. 52, 2603-2612 (2009). 1059 
167.  Wyllie, S., et al. Elevated levels of tryparedoxin peroxidase in antimony 1060 
unresponsive Leishmania donovani field isolates. Mol. Biochem. 1061 
Parasitol. 173, 162-164 (2010). 1062 
168.  Mukhopadhyay, R., et al. Trypanothione overproduction and resistance to 1063 
antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA 93, 1064 
10383-10387 (1996). 1065 
169.  Wyllie, S., Vickers, T. J., & Fairlamb, A. H. Roles of trypanothione S-transferase 1066 
and tryparedoxin peroxidase in resistance to antimonials. Antimicrob. 1067 
Agents Chemother. 52, 1359-1365 (2008). 1068 
170.  Callahan, H. L. & Beverley, S. M. Heavy metal resistance: a new role for P-1069 
glycoproteins in Leishmania. J. Biol. Chem. 266, 18427-18430 (1991). 1070 
171.  Mukherjee, A., et al. Role of ABC transporter MRPA, γ-glutamylcysteine 1071 
synthetase and ornithine decarboxylase in natural antimony-resistant 1072 
isolates of Leishmania donovani. J. Antimicrob. Chemother. 59, 204-211 1073 
(2007). 1074 
172.  El Fadili, K., et al. Role of the ABC transporter MRPA (PGPA) in antimony 1075 
resistance in Leishmania infantum axenic and intracellular amastigotes. 1076 
Antimicrob. Agents Chemother. 49, 1988-1993 (2005). 1077 
173.  Brochu, C., Haimeur, A., & Ouellette, M. The heat shock protein HSP70 and heat 1078 
shock cognate protein HSC70 contribute to antimony tolerance in the 1079 
protozoan parasite Leishmania. Cell Stress & Chaperones 9, 294-303 1080 
(2004). 1081 
174.  Chawla, B., Jhingran, A., Panigrahi, A., Stuart, K. D., & Madhubala, R. 1082 
Paromomycin affects translation and vesicle-mediated trafficking as 1083 
revealed by proteomics of paromomycin -susceptible -resistant 1084 
Leishmania donovani. J. Parasitol. Res. 6, e26660 (2011). 1085 
 30 
175.  Rakotomanga, M., Saint-Pierre-Chazalet, M., & Loiseau, P. M. Alteration of fatty 1086 
acid and sterol metabolism in miltefosine-resistant Leishmania donovani 1087 
promastigotes and consequences for drug-membrane interactions. 1088 
Antimicrob. Agents Chemother. 49, 2677-2686 (2005). 1089 
176.  Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., & Loiseau, P. A. 1090 
Miltefosine afects lipid metabolism in Leishmania donovani 1091 
promastigotes. Antimicrob. Agents Chemother. 51, 1425-1430 (2007). 1092 
177.  Vincent, I. M., et al. Untargeted metabolomic analysis of miltefosine action in 1093 
Leishmania infantum reveals changes to the internal lipid metabolism. Int. 1094 
J. Parasitol. Drugs Drug Resist. 4, 20-27 (2014). 1095 
178.  Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. Miltefosine: a 1096 
review of its pharmacology and therapeutic efficacy in the treatment of 1097 
leishmaniasis. J. Antimicrob. Chemother. 67, 2576-2597 (2012). 1098 
179.  Perez-Victoria, F. J., Gamarro, F., Ouellette, M., & Castanys, S. Functional 1099 
cloning of the miltefosine transporter: A novel P-type phospholipid 1100 
translocase from Leishmania involved in drug resistance. J. Biol. Chem. 1101 
278, 49965-49971 (2003). 1102 
180.  Perez-Victoria, F. J., Castanys, S., & Gamarro, F. Leishmania donovani 1103 
resistance to miltefosine involves a defective inward translocation of the 1104 
drug. Antimicrob. Agents Chemother. 47, 2397-2403 (2003). 1105 
181.  Coelho, A. C., et al. Multiple mutations in heterogeneous miltefosine-resistant 1106 
Leishmania major population as determined by whole genome 1107 
sequencing. PLoS Negl. Trop. Dis. 6, e1512 (2012). 1108 
182.  Perez-Victoria, F. J., Sanchez-Canete, M. P., Castanys, S., & Gamarro, F. 1109 
Phospholipid translocation and miltefosine potency require both L. 1110 
donovani miltefosine transporter and the new protein LdRos3 in 1111 
Leishmania parasites. J. Biol. Chem. 281, 23766-23775 (2006). 1112 
183.  Perez-Victoria, J. M., et al. Alkyl-lysophospholipid resistance in multidrug-1113 
resistant Leishmania tropica and chemosensitization by a novel P-1114 
glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 1115 
45, 2468-2474 (2001). 1116 
184.  Castanys-Munoz, E., Perez-Victoria, J. M., Gamarro, F., & Castanys, S. 1117 
Characterization of an ABCG-like transporter from the protozoan parasite 1118 
Leishmania with a role in drug resistance and transbilayer lipid 1119 
movement. Antimicrob. Agents Chemother. 52, 3573-3579 (2008). 1120 
185.  Canuto, G. A., et al. Multi-analytical platform metabolomic approach to study 1121 
miltefosine mechanism of action and resistance in Leishmania. Anal. 1122 
Bioanal. Chem. 406, 3459-3476 (2014). 1123 
186.  Blum, G., et al. New insight into amphotericin B resistance in Aspergillus terreus. 1124 
Antimicrob. Agents Chemother. 57, 1583-1588 (2013). 1125 
187.  Gray, K. C., et al. Amphotericin primarily kills yeast by simply binding ergosterol. 1126 
Proc. Natl. Acad. Sci. U. S. A 109, 2234-2239 (2012). 1127 
 31 
188.  Odds, F. C., Brown, A. J., & Gow, N. A. Antifungal agents: mechanisms of action. 1128 
Trends Microbiol. 11, 272-279 (2003). 1129 
189.  Prasad, R. & Rawal, M. K. Efflux pump proteins in antifungal resistance. Front 1130 
Pharmacol. 5, 202 (2014). 1131 
190.  Costa, C., Dias, P. J., Sa-Correia, I., & Teixeira, M. C. MFS multidrug transporters 1132 
in pathogenic fungi: do they have real clinical impact? Front Physiol 5, 1133 
197 (2014). 1134 
191.  Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. 1135 
Mechanisms of antifungal drug resistance. Cold Spring Harb. Perspect. 1136 
Med. 5, a019752 (2015). 1137 
192.  Flowers, S. A., et al. Gain-of-function mutations in UPC2 are a frequent cause of 1138 
ERG11 upregulation in azole-resistant clinical isolates of Candida 1139 
albicans. Eukaryot. Cell 11, 1289-1299 (2012). 1140 
193.  Cannon, R. D., et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. 1141 
Rev. 22, 291-321, Table (2009). 1142 
194.  Kwon-Chung, K. J. & Chang, Y. C. Aneuploidy and drug resistance in pathogenic 1143 
fungi. PLoS Pathog. 8, e1003022 (2012). 1144 
195.  Selmecki, A., Gerami-Nejad, M., Paulson, C., Forche, A., & Berman, J. An 1145 
isochromosome confers drug resistance in vivo by amplification of two 1146 
genes, ERG11 and TAC1. Mol. Microbiol. 68, 624-641 (2008). 1147 
196.  Selmecki, A., Forche, A., & Berman, J. Aneuploidy and isochromosome 1148 
formation in drug-resistant Candida albicans. Science 313, 367-370 1149 
(2006). 1150 
197.  Nishikawa, J. L., et al. Inhibiting fungal multidrug resistance by disrupting an 1151 
activator-Mediator interaction. Nature 530, 485-489 (2016). 1152 
198.  Cowen, L. E. The evolution of fungal drug resistance: modulating the trajectory 1153 
from genotype to phenotype. Nat. Rev. Microbiol. 6, 187-198 (2008). 1154 
199.  Sun, H. Y. & Singh, N. Characterisation of breakthrough invasive mycoses in 1155 
echinocandin recipients: an evidence-based review. Int. J. Antimicrob. 1156 
Agents 35, 211-218 (2010). 1157 
200.  Vandeputte, P., Ferrari, S., & Coste, A. T. Antifungal resistance and new 1158 
strategies to control fungal infections. Int. J. Microbiol. 2012, 713687 1159 
(2012). 1160 
 1161 
 1162 
 32 
Table 1.  Diseases caused by eukaryotic microbes, their vectors and front-line treatment options 
Disease Pathogen 
group 
Vector Pathogen Front-line treatments a 
Malaria apicomplexan Anopheline 
mosquitoes 
Plasmodium falciparum Uncomplicated P. falciparum malaria: 
Artemisinin combination therapies (ACTs) 
• Artemether + lumefantrine 
• Artesunate + amodiaquine 
• Artesunate + mefloquine 
• Dihydroartemisinin + piperaquine 
• Artesunate + sulfadoxine + pyrimethamine 
Severe malaria: 
Parenteral (or rectal, children < 6 years) artesunate 
followed by oral ACT (i.m. artemether or i.m. quinine if 
artesunate unavailable) 
P. vivax, P. ovale, P. 
malariae or P. knowlesi 
Blood stage infections: 
Chloroquine (except in areas of chloroquine resistance) 
ACTs (except pregnant women and infants < 6 months) 
Radical cure of liver (hypnozoite) infection: 
Primaquine (close medical supervision with G6PD-
deficient patients) 
African 
trypanosomiasis 
kinetoplastid Tsetse flies Trypanosoma brucei 
gambiense (chronic 
form) 
Haemolymphatic stage (no CNS involvement): 
Pentamidine (i.m.) 
CNS stage: 
Nifurtimox (oral) / eflornithine (i.v.) combination therapy 
(NECT) 
(Melarsoprol if NECT unavailable) 
T. b. rhodesiense 
(acute form) 
Haemolymphatic stage (no CNS involvement): 
Suramin (i.v.) 
CNS stage: 
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Melarsoprol (i.v.) 
American 
trypanosomiasis 
kinetoplastid Triatomine 
bugs 
Trypanosoma cruzi Benznidazole 
Nifurtimox 
Leishmaniasis kinetoplastid Phlebotomine 
sandflies 
Visceral disease 
Leishmania donovani  
L. infantum  
Mucocutaneous 
disease 
L. braziliensis 
L. panamensis  
Cutaneous disease, 
e.g. 
L. major  
L. tropica 
L. mexicana 
L. amazonensis 
Visceral disease: 
Amphotericin B (as liposomal or deoxycholate complex, 
i.v.) 
Miltefosine (oral, contraindicated in pregnancy) 
Paromomycin (i.m.) 
Sodium stibogluconate (SSG) or meglumine 
antimonate, parenteral (except India and Nepal)  
SSG plus paromomycin (East Africa) 
Mucocutaneous: 
SSG (systemic) 
Cutaneous: 
SSG (intralesional) 
Paromomycin (ointment) 
Miltefosine 
Invasive 
Candidiasis 
fungal opportunistic Candida albicans 
Candida glabrata 
Candida parapsilosis 
Echinocandins, Fluconazole, Liposomal Amphotericin B 
Aspergillosis fungal opportunistic Aspergillus fumigatus Voriconazole (Amphotericin B formulations; 
caspofungin; micafungin; posaconazole; itraconazole) 
Pneumocystis 
pneumonia 
fungal opportunistic Pneumocystis carinii Sulfamethoxazole-Trimethoprim (clindamycin-
primaquine)  
Cryptococcal 
meningitis 
fungal opportunistic Cryptococcus 
neoformans 
Amphotericin B plus flucytosine 
Amphotericin B plus fluconazole 
 
a Second line treatment options are given in parentheses 
Data from WHO 58,125-127 and other sources 57,128,129  
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Table 2. Modes of action and mechanisms of drug resistance in eukaryotic microbes 
 
Pathogen Drug and date of 
resistance 
reported 
Drug class and Mode of 
action 
Resistance mechanism 
Plasmodium Chloroquine (CQ) 
 
1957 (SE Asia) 
1960 (S America) 
Mid 1980s (Africa) 
4-Aminoquinoline  
 
Chloroquine interferes with 
the detoxification of haem 
into chemically inert 
haemozoin resulting in 
accumulation of toxic CQ 
ferric haem complex and 
subsequent parasite 
lysis130.   
K76T27 mutation in a Digestive Vacuole-sited, ATP-dependent, 10 
transmembrane domain transporter PfCRT (P. falciparum CQR 
transporter)27; a range of more than 30 different mutations might interact 
epistatically131-133.  These stimulate the active efflux of CQ by mutant 
PfCRT or the passive efflux of diprotonated CQ133.  
 
Other genes contributing to resistance include: the P multidrug resistance 
transporter 1 (PfMDR1) homologue; multipass transmembrane 
transporter CG2; and PfNHE1 and a sodium hydrogen antiporter also 
associated with quinine resistance134. The specific genetic background of 
the parasite and the range of mutations in genes other than PfCRT are 
also key to the manifestation of CQR135.  
 
An independent mutation in PfCRT (C350R) can reverse CQR and also 
increase susceptibility of the parasite to other antimalarials (mefloquine, 
quinine and lumefantrine but not piperiquine136).  
The mutation N326D confers increased resistance to the antimalarial 
amodiaquine40  
Mefloquine 
 
1982 (Thailand) 
Quinoline-4-methanol  
 
Blockade of haemozoin 
formation and binding to 
phospholipids 
PfMDR1 is associated with mefloquine resistance137 but may also 
modulate CQR through compensatory mutations that counteract PfCRT 
mutations that compromise parasite fitness138. 
Artesunate 
Dihydroartemisinin 
Artemether 
 
Sesquiterpene lactone 
endoperoxides.  
 
Dormancy resulting in an extended ring stage phase of development in 
the erythrocyte promotes resistance30-32. 
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200829 (SE Asia) Form a carbon-centred 
free radical or reactive 
electrophilic intermediate 
that alkylates a number of 
malaria proteins139 after 
activation by haem or free 
iron. 
Multiple independent mutations in a gene encoding a Kelch propeller 
protein (Kelch 13) confer resistance33-37. This results in its enhanced 
association with phosphatydylinositol-3-Kinase (PI3K), which is 
subsequently under-ubiquitinated and accumulates along with its lipid 
product, phosphatidylinositol-3-phosphate (PI3P).   
 
The specific genetic background of the parasite and the range of 
mutations in genes other than kelch13 may also be key to the 
manifestation of resistance to artemisinin33 
Sulfadoxine / 
Pyrimethamine  
 
1967 (Thailand); 
1980s (Africa) 
 
 
Antifols.  
 
Sulfadoxine – inhibition of 
dihydropteroate synthase 
(DHPS) 
Pyrimethamine – inhibition  
of dihydrofolate reductase 
(DHFR) 
Synergistic effect on 
thymidylate synthesis 
Decreased affinity of both drugs for their respective targets.  
 
Resistance to sulfadoxine involves DHPS point mutations., DHPS 
variant A437G confers moderate resistance, with the additional 
mutations S436F plus A613S conferring a high level resistance140. 
   
Pyrimethamine clinical resistance involves DHFR point mutations at 
S108N in Africa and SE Asia. Additional mutations that confer high level 
resistance are N51I and C59R141 
 
Increased GTP-cyclohydrolase (CNVs) enhances folate biosynthesis 
compensating for loss of fitness141 
Proguanil DHFR inhibitor High level resistance to cycloguanil (a metabolite of proguanil) involves 
DHFR mutation of serine 108 to threonine. The triple mutations (C59R, 
S108N and I164L) confer cross resistance to both pyrimethamine and 
cycloguanil142. 
 Atovaquone 
(in combination 
with proguanil for 
prophylaxis or 
treatment) 
Cytochrome b inhibitor Effective resistance to atovaquone involves one of a range of mutations 
in cyt b most commonly Y268S. Other mutations associated with such 
resistance include I258M, Y268C, M133I and V259L143 
Suramin Naphthylamine trisulfonic 
acid 
Laboratory-generated resistance mediated through the silencing of 
invariant surface glycoprotein (ISG75), the AP1 adaptin complex, 
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African 
Trypanoso
mes 
 
Mode of action unknown 
lysosomal proteases and major lysosomal transmembrane protein, as 
well as spermidine and N-acetylglucosamine biosynthesis108. 
Pentamidine 
 
Clinical resistance 
is not significant. 
Diamidine 
 
Mode of action unknown 
Resistance is associated with loss of uptake on the P2 
adenine/adenosine transporter144, (AT1)145.   
 
Cross-resistance between melaminophenyl arsenicals and diamidines 
is mediated by aquaglyceroporin 2 (AQP2) 146. A chimeric AQP2/AQP3 
gene is associated with cross resistance to melarsoprol and 
pentamidine in laboratory-generated49,146,147 and clinical isolates148,149 
Melarsoprol 
 
Treatment failures 
have been reported 
in the Democratic 
Republic of Congo, 
Uganda, Angola 
and Sudan2 
Trivalent melaminophenyl 
arsenical.  
 
Forms a cyclic complex 
with trypanothione known 
as MelT46. Inhibits 
trypanothione reductase 
and no doubt other 
targets. 
Resistance is associated with loss of uptake on the P2 
adenine/adenosine transporter144,145.  A non-functional mutant has been 
identified in melarsoprol-resistant field isolates150. 
 
See also AQP in pentamidine section.  
Eflornithine 
(difluoromethyl-
ornithine) 
Fluorinated amino acid. 
 
Mechanism-based 
inhibitor of ornithine 
decarboxylase, required 
for biosynthesis of 
polyamines and 
trypanothione.   
Laboratory-generated resistance is due to loss of a non-essential amino 
acid transporter151,152. There is no detected resistance in 
T. b. gambiense, but there is inherent resistance in some clinical 
isolates of T. b. rhodesiense2. 
 Nifurtimox 
 
(poor efficacy as 
monotherapy; used 
in combination 
therapy with 
Nitrofuran  
 
Prodrug activated by an 
oxygen-insensitive 
mitochondrial 
nitroreductase (NTR)153 to 
A genome-scale RNA interference screen identified NTR and a number 
of other genes possibly associated with NTR function108. NTR is also 
the key resistance determinant in laboratory-generated lines156,157 
showing cross resistance to fexinidazole an oral nitro-imidazole 
currently undergoing Phase II/III clinical trials for HAT. 
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eflornithine 
[NECT]) 
form highly reactive drug 
metabolites154 that kill 
trypanosomes via 
unknown mechanisms155.   
South 
American 
Trypanoso
mes 
Benznidazole, 
Nifurtimox 
 
(natural resistance 
in some T.cruzi 
isolates) 
Nitroheterocyclics 
 
Benznidazole is activated 
by mitochondrial 
NTR153,158 to form 
electrophilic drug 
metabolites159,160 
Drug efflux via an ABCG-like transporter161 
 
The NAD(P)H flavin oxidoreductase (old yellow enzyme) is 
downregulated in resistant lines162,163.  However, this enzyme does not 
reduce benznidazole and only reduces nifurtimox under anaerobic 
conditions164.  
Visceral 
Leishmania
sis 
Sodium 
stibogluconate, 
Meglumine 
antimonite 
 
1990s widespread 
resistance in India 
and Nepal.  Not 
widespread in Sub-
Saharan Africa or 
Brazil 
Pentavalent antimonials  
 
SbV is reduced to SbIII to 
attack intracellular 
amastigotes. Likely to bind 
multiple targets including 
trypanothione 
reductase165,166, 
tryparedoxin peroxidase167 
and CCHC Zinc finger 
proteins166.  
Selection for resistance to trivalent arsenic results in cross-resistance to 
trivalent antimony in vitro61, and in vivo62. Resistance is multifactorial 
through several mechanisms: 
 
• Decreased reduction of SbV to SbIII 
• SbIII is taken up via an aquaglyceroporin73 and modulation of 
expression of aquaglyceroporin 1 affects SbIII susceptibility71-73.   
• Elevated Intracellular trypanothione levels168 or increased 
biosynthetic potential65,66,78,79 . 
• Increased levels of tryparedoxin peroxidase confer resistance to 
SbIII 169 and are found in clinical resistant isolates167 
• MRPA (also known as PgpA or ABCC3), a member of the ATP-
binding cassette (ABC) transporters, is amplified in some resistant 
lines170-172 and sequesters SbIII in an intracellular vacuolar 
compartment close to the flagellar pocket80. 
• chaperones and stress related proteins are upregulated67,68 , 
potentially reducing or repairing cellular damage induced by 
antimonials173 
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 Paromomycin Aminoglycoside 
 
Inhibition of protein 
synthesis 
Added to WHO essential medicines list in 2007. No significant clinical 
resistance. Laboratory-derived resistant lines show decreased drug 
uptake and increased expression of ribosomal proteins174. 
 Miltefosine 
 
2012 (Indian 
subcontinent) 
Alkylphosphocholine 
 
Miltefosine significantly 
perturbs lipid 
metabolism175-177, but the 
targets and precise 
mechanism of action are 
not fully understood178 
Resistance involves either: loss-of-function mutations or under-
expression of an aminophospholipid translocase (LdMT)179-181 or its 
regulatory subunit LdRos3182; or drug efflux by ABC transporters183,184. 
Laboratory-generated resistant lines show alterations in lipid 
metabolism and gene expression 85,185, but WGS in another study 
identified mutations only in the miltefosine transporter, pyridoxal kinase 
and an α-adaptin-like protein176. 
 Amphotericin B 
(deoxycholate or 
liposomal 
formulation) 
Polyene macrolide 
antibiotics 
 
See below 
No significant clinical resistance reported 
Fungi Amphotericin B, 
amphotericin 
deoxycholate 
Polyene macrolide 
antibiotics;  
 
Binds ergosterol more 
avidly than human 
cholesterol disrupting the 
semipermeable membrane 
causing leakage of 
essential metabolites and 
the collapse of 
electrochemical gradients.  
Binding of low density 
lipoprotein receptors and 
amphotericin-mediated 
oxidative damage may 
also contribute. 
Laboratory mutants with lower ergosterol content are less sensitive to 
amphotericin B, but are rare clinically.  Aspergillus terreus is intrinsically 
less amphotericin sensitive but resistant strains have a normal 
ergosterol content suggesting that membrane permeability may not be 
the only mechanism of amphotericin action186. Binding to ergosterol 
might contribute to its mode of action187. 
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Fluconazole, 
Itraconazole, 
Voriconazole, 
Posaconazole, 
Ravuconazole, 
Isavuconazole 
Azoles; 
Bind haem-groups and 
inhibit the P450–mediated 
14α-demethylation 
(Erg11p or Cyp51p) of 
lanosterol in the ergosterol 
biosynthetic pathway. 
Leads to impaired 
membrane permeability, 
membrane protein action 
and cell wall synthesis188. 
Resistance involves the overexpression of drug efflux pumps and point 
mutations in the target ERG11 / CYP51A gene product, along with 
promoter mutations in these genes189-191.  Changes in the levels of three 
main efflux pumps Cdr1, Cdr2 and Mdr1 and mutations in the genes 
encoding the Tac1, Upc2, Pdr1 and Mrr1 transcription factors required 
for efflux pump upregulation, represent major causes of decreased drug 
sensistivity192,193.  This type of azole resistance can be acerbated by 
isochromosome formation and aneuploidy which can increase the copy 
number of key resistance genes such as ERG11 and TAC1194-196 .  
Interference with RNA polymerase II interacting Mediator-complex can 
re-sensitize Pdr1 dependent regulation of drug efflux pumps197  
Chaperone Hsp90 can mitigate against stress induced damage198 and 
also contribute to multidrug resistance with Echinocandins. 
TR34/L98H and the more recently identified TR46/Y121F/T289A alleles 
that confer clinical azole resistance are likely to have arisen from 
environmentally generated mutations 
Caspofungin, 
Micafungin, 
Anidulafungin, 
Cd101 (formerly 
biofungin) 
Echinocandins; 
Cyclic hexapeptides with 
an antifungal bioactive 
lipid side chain that binds 
the fungal specific β-1,3-
glucan synthase Fks cell 
membrane proteins, 
disrupting cell wall 
integrity.   
Resistance through point mutations in two major hotspots in the β-1,3 
glucan synthase genes FKS1 - and, in C. glabrata, FKS286,101,199, these 
reducing drug binding57,181,182. 
Upregulation of cell wall chitin can protect cell wall damage 184-186. 
Hsp90 chaperone can mitigate against stress induced damage170 
Flucytosine (5-
fluorocytosine) 
Fluoropyrimdines; 
converted to 5-fluorouracil 
Resistance results from mutations in the genes encoding cytosine 
permease transporter, cytosine deaminase, which converts 5-FC to 5-
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by cytosine deaminase 
which becomes 
incorporated into RNA 
resulting in inhibition of 
DNA synthesis. 
fluorouracil or the uracil phosphoribosyl transferase required to convert 
5-fluorocytosine into a substrate for nucleic acid synthesis200. Their 
impact is lessened by the use of 5FC in combination therapy. 
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